Experienced in IgG4-Related Disease

Dr. Lee G. Hicks

Hematology Oncology | Oncology
Baptist Health Medical Group
Baptist Health Medical Group Inc
1700 Nicholasville Rd, 
Lexington, KY 
Accepting New Patients
Offers Telehealth

Experienced in IgG4-Related Disease
Baptist Health Medical Group
Baptist Health Medical Group Inc
1700 Nicholasville Rd, 
Lexington, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lee Hicks is a Hematologist Oncology specialist and an Oncologist in Lexington, Kentucky. Dr. Hicks is rated as an Experienced provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Essential Thrombocythemia, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Monoclonal Gammopathy of Undetermined Significance (MGUS). Dr. Hicks is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in KY
Hospital Affiliations
Frankfort Regional Medical Center
Baptist Health Lexington
Baptist Health Richmond
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

BAPTIST HEALTH MEDICAL GROUP INC
1700 Nicholasville Rd, Lexington, KY 40503
Call: 859-260-4390
Other Locations
BAPTIST HEALTH MEDICAL GROUP INC
4071 Tates Creek Centre Dr, Suite 202, Lexington, KY 40517
Call: 859-260-4390

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


9 Clinical Trials

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

2 Total Publications

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 06, 2025
View All 2 Publications
Similar Doctors
Experienced in IgG4-Related Disease
Dr. Snigdha Nutalapati
Hematology Oncology | Oncology
Experienced in IgG4-Related Disease
Dr. Snigdha Nutalapati
Hematology Oncology | Oncology

Kentucky Medical Services Foundation, Inc

800 Rose St, 
Lexington, KY 
 (0.8 miles away)
859-323-5000
Languages Spoken:
English
See accepted insurances

Snigdha Nutalapati is a Hematologist Oncology specialist and an Oncologist in Lexington, Kentucky. Dr. Nutalapati is rated as an Experienced provider by MediFind in the treatment of IgG4-Related Disease. Her top areas of expertise are Pancreatoblastoma, Pancreatic Cancer, Familial Pancreatic Cancer, and Gallbladder Cancer.

VIEW MORE IGG4-RELATED DISEASE DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hicks's expertise for a condition
ConditionClose
    • Distinguished
    • Chronic Lymphocytic Leukemia (CLL)
      Dr. Hicks is
      Distinguished
      . Learn about Chronic Lymphocytic Leukemia (CLL).
      See more Chronic Lymphocytic Leukemia (CLL) experts
    • Essential Thrombocythemia
      Dr. Hicks is
      Distinguished
      . Learn about Essential Thrombocythemia.
      See more Essential Thrombocythemia experts
    • Familial Colorectal Cancer
      Dr. Hicks is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Large-Cell Immunoblastic Lymphoma
      Dr. Hicks is
      Distinguished
      . Learn about Large-Cell Immunoblastic Lymphoma.
      See more Large-Cell Immunoblastic Lymphoma experts
    • Lung Adenocarcinoma
      Dr. Hicks is
      Distinguished
      . Learn about Lung Adenocarcinoma.
      See more Lung Adenocarcinoma experts
    • Monoclonal Gammopathy of Undetermined Significance (MGUS)
      Dr. Hicks is
      Distinguished
      . Learn about Monoclonal Gammopathy of Undetermined Significance (MGUS).
      See more Monoclonal Gammopathy of Undetermined Significance (MGUS) experts
    View All 10 Distinguished Conditions
    • Advanced
    • Acute Mountain Sickness
      Dr. Hicks is
      Advanced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Agranulocytosis
      Dr. Hicks is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Hicks is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anemia
      Dr. Hicks is
      Advanced
      . Learn about Anemia.
      See more Anemia experts
    • Atypical Teratoid Rhabdoid Tumor (ATRT)
      Dr. Hicks is
      Advanced
      . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
      See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
    • Breast Cancer
      Dr. Hicks is
      Advanced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    View All 47 Advanced Conditions
    • Experienced
    • 2q37 Deletion Syndrome
      Dr. Hicks is
      Experienced
      . Learn about 2q37 Deletion Syndrome.
      See more 2q37 Deletion Syndrome experts
    • 47 XYY Syndrome
      Dr. Hicks is
      Experienced
      . Learn about 47 XYY Syndrome.
      See more 47 XYY Syndrome experts
    • Aase Syndrome
      Dr. Hicks is
      Experienced
      . Learn about Aase Syndrome.
      See more Aase Syndrome experts
    • Abruzzo-Erickson Syndrome
      Dr. Hicks is
      Experienced
      . Learn about Abruzzo-Erickson Syndrome.
      See more Abruzzo-Erickson Syndrome experts
    • Acquired Agranulocytosis
      Dr. Hicks is
      Experienced
      . Learn about Acquired Agranulocytosis.
      See more Acquired Agranulocytosis experts
    • Acrodermatitis Enteropathica
      Dr. Hicks is
      Experienced
      . Learn about Acrodermatitis Enteropathica.
      See more Acrodermatitis Enteropathica experts
    View All 264 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved